Nobuhiro Tahara

Dr. Nobuhiro Tahara

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in New England Journal of Medicine
Verified
Journal Article
Closed access
MFMarianna Fontana
Marianna Fontana
JBJohn L. Berk
John L. Berk
JGJulian D. Gillmore
Julian D. Gillmore
RWRonald M. Witteles
Ronald M. Witteles
MGMartha Grogan
Martha Grogan
MMMathew S. Maurer
Mathew S. Maurer
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. In this double-blind, randomized trial, we assigned patients with ATTR-CM in a 1:1 ratio to receive vutrisiran (25 mg) or placebo every 12 weeks for up to 36 months. The primary end point was a composite of death from any cause and recurrent cardiovascular events. Secondary end points included death from any cause, the change from baseline in the distance covered on the 6-minute walk test, and the change from baseline in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score. The efficacy end points were assessed in the overall population and in the monotherapy population (the patients who were not receiving tafamidis at baseline) and were tested hierarchically. A total of 655 patients underwent randomization; 326 were assigned to receive vutrisiran and 329 to receive placebo. Vutrisiran treatment led to a lower risk of death from any cause and recurrent cardiovascular events than placebo (hazard ratio in the overall population, 0.72; 95% confidence interval [CI], 0.56 to 0.93; P = 0.01; hazard ratio in the monotherapy population, 0.67; 95% CI, 0.49 to 0.93; P = 0.02) and a lower risk of death from any cause through 42 months (hazard ratio, 0.65; 95% CI, 0.46 to 0.90; P = 0.01). A primary end-point event occurred in 163 patients in the vutrisiran group and in 202 in the placebo group. In the overall population, treatment with vutrisiran resulted in less of a decline in the distance covered on the 6-minute walk test than placebo (least-squares mean difference, 26.5 m; 95% CI, 13.4 to 39.6; P<0.001) and less of a decline in the KCCQ-OS score (least-squares mean difference, 5.8 points; 95% CI, 2.4 to 9.2; P<0.001). Similar benefits were observed in the monotherapy population. The incidence of adverse events was similar in the two groups (99% in the vutrisiran group and 98% in the placebo group); serious adverse events occurred in 62% of the patients in the vutrisiran group and in 67% of those in the placebo group. Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B ClinicalTrials.gov number, NCT04153149.).

26 October 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
MMMathew S. Maurer
Mathew S. Maurer
PKParag Kale
Parag Kale
MFMarianna Fontana
Marianna Fontana
JBJohn L Berk
John L Berk
MGMartha Grogan
Martha Grogan
AIAPOLLO-B Trial Investigators
APOLLO-B Trial Investigators
Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. In this phase 3, double-blind, randomized trial, we assigned patients with hereditary, also known as variant, or wild-type ATTR cardiac amyloidosis, in a 1:1 ratio, to receive patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks for 12 months. A hierarchical procedure was used to test the primary and three secondary end points. The primary end point was the change from baseline in the distance covered on the 6-minute walk test at 12 months. The first secondary end point was the change from baseline to month 12 in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score (with higher scores indicating better health status). The second secondary end point was a composite of death from any cause, cardiovascular events, and change from baseline in the 6-minute walk test distance over 12 months. The third secondary end point was a composite of death from any cause, hospitalizations for any cause, and urgent heart failure visits over 12 months. A total of 360 patients were randomly assigned to receive patisiran (181 patients) or placebo (179 patients). At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate of median difference, 14.69 m; 95% confidence interval [CI], 0.69 to 28.69; P = 0.02); the KCCQ-OS score increased in the patisiran group and declined in the placebo group (least-squares mean difference, 3.7 points; 95% CI, 0.2 to 7.2; P = 0.04). Significant benefits were not observed for the second secondary end point. Infusion-related reactions, arthralgia, and muscle spasms occurred more often among patients in the patisiran group than among those in the placebo group. In this trial, administration of patisiran over a period of 12 months resulted in preserved functional capacity in patients with ATTR cardiac amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO-B ClinicalTrials.gov number, NCT03997383.).

1 April 2007 in JACC
Verified
Journal Article
Closed access
NTNobuhiro Tahara
Nobuhiro Tahara
HKHisashi Kai
Hisashi Kai
SYSho-Ichi Yamagishi
Sho-Ichi Yamagishi
MMMinori Mizoguchi
Minori Mizoguchi
HNHiroyuki Nakaura
Hiroyuki Nakaura
TITsutomu Imaizumi
Tsutomu Imaizumi

1 December 2010 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
NTNobuhiro Tahara
Nobuhiro Tahara
ATAtsuko Tahara
Atsuko Tahara
YNYoshikazu Nitta
Yoshikazu Nitta
NKNorihiro Kodama
Norihiro Kodama
MMMinori Mizoguchi
Minori Mizoguchi
TITsutomu Imaizumi
Tsutomu Imaizumi

26 January 2012 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
NTNobuhiro Tahara
Nobuhiro Tahara
SYSho‐Ichi Yamagishi
Sho‐Ichi Yamagishi
TMTakanori Matsui
Takanori Matsui
MTMasayoshi Takeuchi
Masayoshi Takeuchi
YNYoshikazu Nitta
Yoshikazu Nitta
TITsutomu Imaizumi
Tsutomu Imaizumi
SUMMARY: Background: Advanced glycation end products (AGEs) evoke oxidative stress generation and inflammatory reactions, thus being involved in vascular complications in diabetes. Since oxidative stress and inflammation impair insulin actions as well, it is conceivable that AGEs may play some role in insulin resistance. However, there is no clinical study to examine the relationship between serum levels of AGEs and insulin resistance. This study investigated whether serum AGE levels were independent correlates of insulin resistance in humans. Methods: Three hundred twenty‐two nondiabetic Japanese subjects (216 male and 106 female; mean age 61.5 ± 9.1 years) underwent a complete history and physical examination, determinations of blood chemistries, anthropometric and metabolic variables, including AGEs. Serum AGE levels were examined with an enzyme‐linked immunosorbent assay. Results: Mean serum AGE levels were 8.96 ± 2.57 U/mL. In univariate analysis, waist circumference, diastolic blood pressure (BP), mean BP, AGEs, low‐density lipoprotein (LDL) cholesterol, triglycerides, high‐density lipoprotein (HDL) cholesterol (inversely), hemoglobin A1c (GHb), creatinine clearance, uric acid, and high sensitivity C‐reactive protein were significantly associated with insulin resistance evaluated by homeostasis model assessment of insulin resistance (HOMA‐IR) index. After performing multiple regression analysis, waist circumference (P < 0.001), GHb (P < 0.001), triglycerides (P < 0.001), and AGEs (P < 0.01) still remained significant independently. When age‐adjusted HOMA‐IR levels stratified by AGE tertiles were compared using ANCOVA, a significant trend was demonstrated in both males and females. Conclusion: The present study demonstrated for the first time that serum AGE levels were one of the independent correlates of HOMA‐IR index, thus suggesting that AGEs may play some pathological role in insulin resistance in humans.

14 November 2012 in Diabetes Care
Verified
Journal Article
Open access
PDF file
NTNobuhiro Tahara
Nobuhiro Tahara
SYSho-Ichi Yamagishi
Sho-Ichi Yamagishi
MTMasayoshi Takeuchi
Masayoshi Takeuchi
AHAkihiro Honda
Akihiro Honda
ATAtsuko Tahara
Atsuko Tahara
TITsutomu Imaizumi
Tsutomu Imaizumi
OBJECTIVE Advanced glycation end products (AGEs) evoke inflammatory reactions, contributing to the development and progression of atherosclerosis. We investigated the relationship between serum AGE level and vascular inflammation. RESEARCH DESIGN AND METHODS The study involved 275 outpatients at Kurume University, Japan (189 males and 86 females; mean age 61.2 ± 8.8 years) who underwent complete history and physical examinations and determinations of blood chemistry and anthropometric variables, including AGEs. Serum AGE level was examined by enzyme-linked immunosorbent assay. Vascular [18F]fluorodeoxyglucose (FDG) uptake, an index of vascular inflammation, was measured as blood-normalized standardized uptake value, known as the target-to-background ratio (TBR), by FDG–positron emission tomography (FDG-PET). Furthermore, we examined whether the changes in serum AGE level after treatment with oral hypoglycemia agents (OHAs) were correlated with those of TBR in another 18 subjects whose AGE value was >14.2 units/mL (mean ± 2 SD). RESULTS Mean serum AGE level and carotid TBR values were 9.15 ± 2.53 and 1.43 ± 0.22 units/mL, respectively. Multiple stepwise regression analysis revealed that TBR was independently correlated with AGEs (P < 0.001), carotid intima-media thickness (P < 0.01), and BMI (P < 0.02). When age- and sex-adjusted AGE values stratified by TBR tertiles were compared using ANCOVA, a significant trend was observed (P < 0.01). In addition, the changes in AGEs after OHA treatment were positively (r = 0.50, P < 0.05) correlated with those in TBR value. CONCLUSIONS The current study reveals that serum AGE level is independently associated with vascular inflammation evaluated by FDG-PET, suggesting that circulating AGE value may be a biomarker that could reflect vascular inflammation within an area of atherosclerosis.